Changxian X. Li

Guangzhou Road 300
Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

USP1-mediated lipophagy-lipogenesis axis drives cholangiocarcinoma progression and immune evasion.

USP1-mediated lipophagy-lipogenesis axis drives cholangiocarcinoma progression and immune evasion.

Journal: Journal for immunotherapy of cancer

Published: May 17, 2026

Kaempferide in Alpinia officinarum Hance Exerts Anti-Hepatocellular Carcinoma Activity by Inhibiting Mitophagy Through Downregulation of BNIP3L.

Kaempferide in Alpinia officinarum Hance Exerts Anti-Hepatocellular Carcinoma Activity by Inhibiting Mitophagy Through Downregulation of BNIP3L.

Journal: Journal of cellular and molecular medicine

Published: March 09, 2026

CircUBAP2 promotes intrahepatic cholangiocarcinoma progression via PRMT1-p65 methylation and the miR-642b-5p/IL-1β axis.

CircUBAP2 promotes intrahepatic cholangiocarcinoma progression via PRMT1-p65 methylation and the miR-642b-5p/IL-1β axis.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: March 04, 2026

CME-KGDTI: integrating clustered mutations into knowledge graph embedding for drug-target interaction prediction.

CME-KGDTI: integrating clustered mutations into knowledge graph embedding for drug-target interaction prediction.

Journal: BioData mining

Published: January 01, 2026

Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial.

Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial.

Journal: BMJ open gastroenterology

Published: May 02, 2025

Surgical treatment and survival analyses of intrahepatic cholangiocarcinoma

Surgical treatment and survival analyses of intrahepatic cholangiocarcinoma

Journal: Zhonghua wai ke za zhi [Chinese journal of surgery]

Published: March 09, 2025

Aldose reductase -mediated HUR ubiquitination enhances exosome release and hepatic fibrosis via ROS/PI3K/AKT pathway.

Aldose reductase -mediated HUR ubiquitination enhances exosome release and hepatic fibrosis via ROS/PI3K/AKT pathway.

Journal: Free radical biology & medicine

Published: March 03, 2025

NRXN3 regulates pyroptosis in intrahepatic cholangiocarcinoma via mediating the phospho-dependent ubiquitination and degradation of caspase-3.

NRXN3 regulates pyroptosis in intrahepatic cholangiocarcinoma via mediating the phospho-dependent ubiquitination and degradation of caspase-3.

Journal: Journal of advanced research

Published: February 19, 2025

USP28 promotes tumor progression and glycolysis by stabilizing PKM2/Hif1-α in cholangiocarcinoma.

USP28 promotes tumor progression and glycolysis by stabilizing PKM2/Hif1-α in cholangiocarcinoma.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: September 30, 2024

Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers.

Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers.

Journal: Cancer science

Published: July 18, 2024

The role of exercise-based prehabilitation in enhancing surgical outcomes for patients with digestive system cancers: a meta-analysis.

The role of exercise-based prehabilitation in enhancing surgical outcomes for patients with digestive system cancers: a meta-analysis.

Journal: BMC gastroenterology

Published: May 11, 2024

Surgical treatment and prognosis analysis of hilar cholangiocarcinoma

Surgical treatment and prognosis analysis of hilar cholangiocarcinoma

Journal: Zhonghua wai ke za zhi [Chinese journal of surgery]

Published: March 03, 2024

Showing 1-12 of 49

Last Updated: 09/26/2026